Warning! GuruFocus detected
2 Severe warning signs
with MGX.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Metagenomi Inc
NAICS : 541713
SIC : 2834
ISIN : US59102M1045
Description
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.42 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.48 | |||||
| Beneish M-Score | -2.43 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 482.7 | |||||
| 3-Year EBITDA Growth Rate | -53.9 | |||||
| 3-Year EPS without NRI Growth Rate | -37.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49 | |||||
| 9-Day RSI | 36.86 | |||||
| 14-Day RSI | 33.88 | |||||
| 3-1 Month Momentum % | -37.27 | |||||
| 6-1 Month Momentum % | 3.5 | |||||
| 12-1 Month Momentum % | -78.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.91 | |||||
| Quick Ratio | 6.91 | |||||
| Cash Ratio | 6.66 | |||||
| Days Sales Outstanding | 11.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.7 | |||||
| Shareholder Yield % | -155.74 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -170 | |||||
| Net Margin % | -149.27 | |||||
| FCF Margin % | -214.53 | |||||
| ROE % | -43.36 | |||||
| ROA % | -21.11 | |||||
| ROIC % | -66.95 | |||||
| 3-Year ROIIC % | -132.09 | |||||
| ROC (Joel Greenblatt) % | -144.2 | |||||
| ROCE % | -28.25 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.86 | |||||
| PB Ratio | 0.22 | |||||
| Price-to-Tangible-Book | 0.22 | |||||
| EV-to-EBIT | 1.68 | |||||
| EV-to-EBITDA | 1.79 | |||||
| EV-to-Revenue | -2.85 | |||||
| EV-to-Forward-Revenue | 0.98 | |||||
| EV-to-FCF | 1.33 | |||||
| Price-to-Net-Current-Asset-Value | 0.31 | |||||
| Price-to-Net-Cash | 0.33 | |||||
| Earnings Yield (Greenblatt) % | 59.52 | |||||
| FCF Yield % | -214.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MGX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Metagenomi Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 52.295 | ||
| EPS (TTM) ($) | -2.62 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 104.47 | ||
| 14-Day RSI | 33.88 | ||
| 14-Day ATR ($) | 0.140815 | ||
| 20-Day SMA ($) | 1.626 | ||
| 12-1 Month Momentum % | -78.94 | ||
| 52-Week Range ($) | 1.23 - 10.5 | ||
| Shares Outstanding (Mil) | 37.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Metagenomi Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Metagenomi Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Metagenomi Inc Frequently Asked Questions
What is Metagenomi Inc(MGX)'s stock price today?
The current price of MGX is $1.40. The 52 week high of MGX is $10.50 and 52 week low is $1.23.
When is next earnings date of Metagenomi Inc(MGX)?
The next earnings date of Metagenomi Inc(MGX) is 2025-05-30 Est..
Does Metagenomi Inc(MGX) pay dividends? If so, how much?
Metagenomi Inc(MGX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers